◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › BHVN

Biohaven Ltd. (BHVN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-15

Biohaven Ltd. (BHVN) operates in the Biotechnology industry and is headquartered in New Haven, United States with about 274 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, BHVN reported $0M in revenue and ($739M) in net income.

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

Interactive charts & full statements →

BHVN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($745M)($885M)($436M)($568M)
Net Income($739M)($846M)($408M)($570M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BHVN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($130M)($143M)($169M)($212M)($222M)
Net Income($130M)($146M)($173M)($198M)($222M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BHVN Free Cash Flow History

BHVN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$451M$615M$513M$662M
Total Liabilities$399M$192M$85M$123M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BHVN viewer.

Other Companies in Biotechnology

← BHSTAll stocksBIAF →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.